Four-Year Glaucoma Implant Data Show 37% IOP Cut, 86% Drop-Free
SGP sits 41% above its 52-week low of $17.06.
Summary
SpyGlass reported 4-year first-in-human results for its lead BIM-IOL System: mean IOP fell 37% (25.1 to 15.9 mmHg) across all three dose groups, 86% of the 21 evaluable patients stayed off all topical glaucoma drops, 90% kept 20/25 vision or better, and there were no product-related adverse events. This is the first sustained-delivery glaucoma implant to show four years of durable safety and efficacy, a meaningful de-risking for a Phase 3 asset in a company with roughly an $800M market cap. It follows the October 1 acquisition of supplier Advanced Vision Science for $13M in cash, which secured manufacturing capacity for the Phase 3 program. The company plans a 505(b)(2) NDA submission and is still enrolling Phase 3 trials; those enrollment and data milestones are the next real proof points. The main caveat is that this is a small single-center FIH study (N=21), not the pivotal dataset.
At the time of this announcement, SGP was trading at $24.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $802.8M. The 52-week trading range was $17.06 to $30.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.